Beckman Coulter Inc has signed several new three-year agreements with Premier, Inc. The new contracts-which include pricing agreements for Beckman Coulter’s chemistry, immunoassay, hematology and automation systems, services and supplies-are expected to generate approximately $130 million in revenue per year for Beckman Coulter.

“These agreements provide Premier members with access to an extensive menu of product offerings, from routine tests like complete blood counts to specialty tests for cancer, cardiovascular disease, diabetes and more,” said Robert Kleinert, vice president of the Americas for the clinical diagnostics division of Beckman Coulter. “In addition, the agreements now encompass our full range of automation equipment, including more than 30 systems and modules. These systems and tests are uniquely suited to help improve lab processes to make hospitals and health networks more efficient and cost-effective.”

The agreements include Beckman Coulter’s new UniCel DxI 800 Access immunoassay system, which can perform up to 400 tests per hour-the highest throughput of any random-access immunoassay system on the market. The DxI 800 test menu features approximately 40 tests in the United States, including cardiac, cancer, anemia, infectious disease, reproductive and other endocrine tests.

Other new systems on contract include the LH 1500 series hematology automation system, which manages the entire hematology testing process, from pre-analytical sorting to post-analytical storage; the Synchron LXi 725 clinical system, which combines chemistry and immunoassay testing with data management and automated sample handling on a single platform; and the Coulter LH 500 hematology analyzer for fast, accurate blood cell counts.

In addition, Premier members will continue to access contracts for hundreds of other Beckman Coulter tests and instruments, such as the Access 2 immunoassay system, Coulter LH 700 series hematology analyzers and the Synchron LX20 PRO clinical system.